FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...

The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: “The approval of FLUMIST for self-administration is an important step forward in making vaccines more accessible ...

FluMist is a nasally-administered influenza vaccine that is indicated for active immunization to prevent influenza disease in individuals 2 to 49 years of age.

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

The applause mentioned above was for AstraZeneca’s Phase 3 NIAGARA study in bladder cancer, which showed that giving patients the checkpoint inhibitor Imfinzi — both before and after surgery ...

AstraZeneca's FluMist influenza vaccine, which can be self-administered. Experts hope an option for at-home flu vaccination ...

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...

(Alliance News) - AstraZeneca PLC on Friday announced that its influenza vaccine FluMist has been approved for self-administration in the US. The Cambridge, England-based biopharmaceutical company ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...